{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:37:01Z","timestamp":1760852221972},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,3,23]],"date-time":"2006-03-23T00:00:00Z","timestamp":1143072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00280-006-0199-4","type":"journal-article","created":{"date-parts":[[2006,3,22]],"date-time":"2006-03-22T13:37:50Z","timestamp":1143034670000},"page":"517-526","source":"Crossref","is-referenced-by-count":11,"title":["Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism"],"prefix":"10.1007","volume":"58","author":[{"given":"B. J.","family":"Cusack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gambliel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Musser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hadjokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Shadle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Charlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. D.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,23]]},"reference":[{"key":"199_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0167-4889(02)00391-9","volume":"1593","author":"X Brazzolotto","year":"2003","unstructured":"Brazzolotto X, Andriollo M, Guiraud P, Favier A, Moulis JM (2003) Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 1593:209\u2013218","journal-title":"Biochim Biophys Acta"},{"key":"199_CR2","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/0006-2952(85)90315-6","volume":"34","author":"NE Capps","year":"1985","unstructured":"Capps NE, Nigdikar S, Burns JH, Walker EJ, Dow JW (1985) Characterization of digoxin binding and daunorubicin uptake by isolated mature rat cardiac myocytes. Biochem Pharmacol 34:1957\u20131961","journal-title":"Biochem Pharmacol"},{"key":"199_CR3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jn\/127.2.238","volume":"127","author":"OS Chen","year":"1997","unstructured":"Chen OS, Schalinske KL, Eisenstein RS (1997) Dietary iron intake modulates the activity of iron regulatory proteins and the abundance of ferritin and mitochondrial aconitase in rat liver. J Nutr 127:238\u2013248","journal-title":"J Nutr"},{"key":"199_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jn\/128.3.525","volume":"128","author":"OS Chen","year":"1998","unstructured":"Chen OS, Blemings KP, Schalinske KL, Eisenstein RS (1998) Dietary iron intake rapidly influences iron regulatory proteins, ferritin subunits and mitochondrial aconitase in rat liver. J Nutr 128:525\u2013535","journal-title":"J Nutr"},{"key":"199_CR5","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.1074\/jbc.M310106200","volume":"279","author":"G Corna","year":"2004","unstructured":"Corna G, Santambrogio P, Minotti G, Cairo G (2004) Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279:13738\u201313745","journal-title":"J Biol Chem"},{"key":"199_CR6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF00254234","volume":"22","author":"BJ Cusack","year":"1988","unstructured":"Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD (1988) Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 22:294\u2013298","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00686407","volume":"30","author":"BJ Cusack","year":"1992","unstructured":"Cusack BJ, Young SP, Loseke VL, Hurty MR, Beals L, Olson RD (1992) Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 30:145\u2013148","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00685876","volume":"32","author":"BJ Cusack","year":"1993","unstructured":"Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53\u201358","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00686550","volume":"35","author":"BJ Cusack","year":"1995","unstructured":"Cusack BJ, Young SP, Olson RD (1995) Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother Pharmacol 35:213\u2013218","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s002800050606","volume":"39","author":"BJ Cusack","year":"1997","unstructured":"Cusack BJ, Young SP, Vestal RE, Olson RD (1997) Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cancer Chemother Pharmacol 39:505\u2013512","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1385\/CT:2:2:099","volume":"2","author":"BJ Cusack","year":"2002","unstructured":"Cusack BJ, Young SP, Gabliel H, Olson RD (2002) Effect of aging on cardiac contractility in a rat model of chronic daunorubicin cardiotoxicity. Cardiovasc Toxicol 2:99\u2013109","journal-title":"Cardiovasc Toxicol"},{"key":"199_CR12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-002-0544-1","volume":"51","author":"BJ Cusack","year":"2003","unstructured":"Cusack BJ, Musser B, Gambliel H, Hadjokas NE, Olson RD (2003) Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats. Cancer Chemother Pharmacol 51:139\u2013146","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/019262339602400402","volume":"24","author":"P Della Torre","year":"1996","unstructured":"Della Torre P, Podesta A, Pinciroli G, Iatropoulos MJ, Mazue G (1996) Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats. Toxicol Pathol 24:398\u2013402","journal-title":"Toxicol Pathol"},{"key":"199_CR14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s002800050958","volume":"44","author":"P Della Torre","year":"1999","unstructured":"Della Torre P, Imondi AR, Bernardi C, Podesta A, Moneta D, Riflettuto M, Mazue G (1999) Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel. Cancer Chemother Pharmacol 44:138\u2013142","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0006-2952(90)90154-D","volume":"39","author":"H Harada","year":"1990","unstructured":"Harada H, Cusack BJ, Olson RD, Stroo W, Azuma J, Hamaguchi T, Schaffer SW (1990) Taurine deficiency and doxorubicin: interaction with the cardiac sarcolemmal calcium pump. Biochem Pharmacol 39:745\u2013751","journal-title":"Biochem Pharmacol"},{"key":"199_CR16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","volume":"117","author":"MW Hentze","year":"2004","unstructured":"Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285\u2013297","journal-title":"Cell"},{"key":"199_CR17","first-page":"3436","volume":"41","author":"EH Herman","year":"1981","unstructured":"Herman EH, Ferrans VJ (1981) Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+\/\u2212)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res 41:3436\u20133440","journal-title":"Cancer Res"},{"key":"199_CR18","first-page":"85","volume":"31","author":"EH Herman","year":"1981","unstructured":"Herman EH, Ferrans VJ, Jordan W, Ardalan B (1981) Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31:85\u201397","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"199_CR19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00686629","volume":"35","author":"EH Herman","year":"1994","unstructured":"Herman EH, Zhang J, Ferrans VJ (1994) Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 35:93\u2013100","journal-title":"Cancer Chemother Pharmacol"},{"key":"199_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.0000109213.10461.F6","volume":"109","author":"Y Huang","year":"2004","unstructured":"Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN (2004) Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 109:97\u2013102","journal-title":"Circulation"},{"key":"199_CR21","first-page":"4200","volume":"56","author":"AR Imondi","year":"1996","unstructured":"Imondi AR, Della Torre P, Mazue G, Sullivan TM, Robbins TL, Hagerman LM, Podesta A, Pinciroli G (1996) Dose\u2013response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56:4200\u20134204","journal-title":"Cancer Res"},{"key":"199_CR22","doi-asserted-by":"crossref","first-page":"17179","DOI":"10.1074\/jbc.M111604200","volume":"277","author":"S Kotamraju","year":"2002","unstructured":"Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179\u201317187","journal-title":"J Biol Chem"},{"key":"199_CR23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/mol.62.4.888","volume":"62","author":"JC Kwok","year":"2002","unstructured":"Kwok JC, Richardson DR (2002) Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 62:888\u2013900","journal-title":"Mol Pharmacol"},{"key":"199_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.emboj.7600041","volume":"23","author":"EG Meyron-Holtz","year":"2004","unstructured":"Meyron-Holtz EG, Ghosh MC, Iwai K, LaVaute T, Brazzolotto X, Berger UV, Land W, Ollivierre-Wilson H, Grinberg A, Love P, Rouault TA (2004) Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J 23:386\u2013395","journal-title":"EMBO J"},{"key":"199_CR25","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1126\/science.1103786","volume":"306","author":"EG Meyron-Holtz","year":"2004","unstructured":"Meyron-Holtz EG, Ghosh MC, Rouault TA (2004) Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 306:2087\u20132090","journal-title":"Science"},{"key":"199_CR26","first-page":"1455","volume":"27","author":"JG Mill","year":"1994","unstructured":"Mill JG, Vassallo DV, Leite CM, Campagnaro P (1994) Influence of the sarcoplasmic reticulum on the inotropic responses of the rat myocardium resulting from changes in rate and rhythm. Braz J Med Biol Res 27:1455\u20131465","journal-title":"Braz J Med Biol Res"},{"key":"199_CR27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI117833","volume":"95","author":"G Minotti","year":"1995","unstructured":"Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, Possati G (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 95:1595\u20131605","journal-title":"J Clin Invest"},{"key":"199_CR28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1096\/fasebj.12.7.541","volume":"12","author":"G Minotti","year":"1998","unstructured":"Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase\/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541\u2013552","journal-title":"FASEB J"},{"key":"199_CR29","first-page":"8422","volume":"61","author":"G Minotti","year":"2001","unstructured":"Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422\u20138428","journal-title":"Cancer Res"},{"key":"199_CR30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185\u2013229","journal-title":"Pharmacol Rev"},{"key":"199_CR31","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1096\/fasebj.4.13.2210154","volume":"4","author":"RD Olson","year":"1990","unstructured":"Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076\u20133086","journal-title":"FASEB J"},{"key":"199_CR32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.taap.2004.06.021","volume":"202","author":"G Papanikolaou","year":"2005","unstructured":"Papanikolaou G, Pantopoulos K (2005) Iron metabolism and toxicity. Toxicol Appl Pharmacol 202:199\u2013211","journal-title":"Toxicol Appl Pharmacol"},{"key":"199_CR33","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/01.CIR.99.8.1077","volume":"99","author":"NG Perez","year":"1999","unstructured":"Perez NG, Hashimoto K, McCune S, Altschuld RA, Marban E (1999) Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation 99:1077\u20131083","journal-title":"Circulation"},{"key":"199_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0300-483X(02)00383-9","volume":"180","author":"JL Quiles","year":"2002","unstructured":"Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC (2002) Antioxidant nutrients and adriamycin toxicity. Toxicology 180:79\u201395","journal-title":"Toxicology"},{"key":"199_CR35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00059-002-2360-0","volume":"27","author":"MJ Sole","year":"2002","unstructured":"Sole MJ, Jeejeebhoy KN (2002) Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz 27:174\u2013178","journal-title":"Herz"},{"key":"199_CR36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM198809223191203","volume":"319","author":"JL Speyer","year":"1988","unstructured":"Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745\u2013752","journal-title":"N Engl J Med"},{"key":"199_CR37","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318\u20131332","journal-title":"J Clin Oncol"},{"key":"199_CR38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1006\/jmcc.1994.1136","volume":"26","author":"EE Voest","year":"1994","unstructured":"Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A (1994) Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 26:1179\u20131185","journal-title":"J Mol Cell Cardiol"},{"key":"199_CR39","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0006-2952(96)00894-5","volume":"53","author":"G Weiss","year":"1997","unstructured":"Weiss G, Kastner S, Brock J, Thaler J, Grunewald K (1997) Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Biochem Pharmacol 53:1419\u20131424","journal-title":"Biochem Pharmacol"},{"key":"199_CR40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1113\/jphysiol.2002.024190","volume":"543","author":"SH Woo","year":"2002","unstructured":"Woo SH, Cleemann L, Morad M (2002) Ca2+ current-gated focal and local Ca2+ release in rat atrial myocytes: evidence from rapid 2-D confocal imaging. J Physiol 543:439\u2013453","journal-title":"J Physiol"},{"key":"199_CR41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/mol.105.013383","volume":"68","author":"X Xu","year":"2005","unstructured":"Xu X, Persson HL, Richardson DR (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68:261\u2013271","journal-title":"Mol Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0199-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0199-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0199-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T09:13:27Z","timestamp":1586769207000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0199-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,23]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["199"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0199-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,23]]}}}